Ceftolozane/tazobactam positive data for UTI and cIAI infections - Cubist
Cubist Pharmaceuticals, Inc. has announced the first detailed results from positive pivotal Phase III clinical trials of its antibiotic candidate ceftolozane/tazobactam in development to treat serious infections including complicated Urinary Tract Infections (cUTI) and complicated Intra-Abdominal Infections (cIAI). Results will be presented at the 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) being held in Barcelona May 10 - 13. These new data include additional details on ceftolozane/tazobactam�s clinical cure and/or microbiological eradication rates, which met or exceeded pre-specified FDA and European Medicines Agency (EMA) non-inferiority margins, as well as details on the overall safety profile. Additionally, for the first time Cubist is presenting data on microbiological eradication of key problematic Gram-negative pathogens, including Pseudomonas aeruginosa and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (E. coli) and Klebsiella pneumoniae.
Microbiological eradication rates for ceftolozane/tazobactam were 84% - 100% in these pathogens across the cUTI and cIAI clinical trials.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins